Study identifier:2993-119
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects with Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Phase 3
No
exenatide
All
456
Interventional
18 Years - 70 Years
Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
N/A
This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.
Location
Location
Portland, OR, United States
Location
New York, NY, United States
Location
Chula Vista, CA, United States
Location
Camp Hill, PA, United States
Location
Los Gatos, CA, United States
Location
Ocala, FL, United States
Location
Chesterfield, MO, United States
Location
Redwood City, CA, United States
Arms | Assigned Interventions |
---|---|
Experimental: Exenatide Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination | Drug: exenatide subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination Other Name: Byetta Other Name: exendin-4 Other Name: AC2993 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.